Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics Holdings Ltd. has announced the extension of its partnership with the Burnet Diagnostics Initiative to produce a point-of-care test and related technology for monitoring liver health in a US clinical trial. The test, which measures Alanine Transaminase (ALT) levels to indicate liver injury, is expected to generate fees for Lumos between US$0.7 million and US$1.0 million over the next 9-12 months. This collaboration demonstrates Lumos’ continued commitment to advancing rapid diagnostic solutions and could lead to further engagement in future trials.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
